Traders Buy Large Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the recipient of unusually large options trading on Monday. Stock investors purchased 13,040 call options on the stock. This is an increase of approximately 42% compared to the typical volume of 9,161 call options.

Insiders Place Their Bets

In related news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $6.22, for a total transaction of $71,200.34. Following the transaction, the director now owns 7,098,428 shares of the company's stock, valued at approximately $44,152,222.16. This trade represents a 0.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Tina Marriott sold 6,000 shares of the business's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $7.00, for a total value of $42,000.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares of the company's stock, valued at approximately $3,647,966. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 107,788 shares of company stock valued at $724,691 over the last 90 days. Insiders own 15.75% of the company's stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several large investors have recently made changes to their positions in RXRX. Allspring Global Investments Holdings LLC bought a new stake in Recursion Pharmaceuticals during the 3rd quarter valued at about $25,000. Farther Finance Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after acquiring an additional 4,091 shares in the last quarter. KBC Group NV raised its holdings in Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company's stock worth $50,000 after acquiring an additional 3,377 shares during the last quarter. Amalgamated Bank lifted its position in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company's stock valued at $54,000 after acquiring an additional 2,459 shares in the last quarter. Finally, San Luis Wealth Advisors LLC purchased a new stake in Recursion Pharmaceuticals during the 3rd quarter valued at $69,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RXRX has been the subject of a number of analyst reports. Jefferies Financial Group dropped their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a report on Tuesday, September 3rd. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Finally, Leerink Partners decreased their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a report on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $9.25.

Recursion Pharmaceuticals Stock Up 15.9 %

Recursion Pharmaceuticals stock traded up $0.96 during trading hours on Monday, hitting $6.99. 20,711,162 shares of the stock traded hands, compared to its average volume of 6,790,291. Recursion Pharmaceuticals has a one year low of $5.60 and a one year high of $15.74. The firm's 50-day moving average price is $6.76 and its two-hundred day moving average price is $7.18. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The company has a market cap of $2.00 billion, a PE ratio of -4.57 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The firm had revenue of $26.08 million for the quarter, compared to analysts' expectations of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business's quarterly revenue was up 147.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.43) EPS. On average, research analysts forecast that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.